Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Haemonetics says FDA clears vascular closure device

19 October 2026 · By · Wire by Fusion42

Published

19 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 19 October 2026 · Fusion42 review

Haemonetics received FDA approval for its PerQseal Elite vascular closure device designed to seal arterial openings in minimally invasive heart and vascular procedures, enhancing procedural safety without leaving permanent implants.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The FDA approval opens immediate market access for vascular closure tech without permanent implants, so you need to engage cardiology teams to evaluate PerQseal Elite for quicker adoption.

◆ Coverage

2 sources · 19 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalvascular-closuremedical-devicescardiovascularmedtech